NCT06966154View on ClinicalTrials.gov

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2028

Conditions
Natural Killer/T-cell LymphomaRelapsed or Refractory Lymphoma Including ENKL
Interventions
DRUG

tislezumab

Tislelizumab will be administered intravenously at a fixed dose of 200 mg every 3 weeks (Q3W).

DRUG

golidocitinib

"Golidocitinib: Dose-escalating oral regimens:~Dose level A: 150 mg every other day (QOD). Dose level B: 150 mg once daily (QD)."

DRUG

Selinexor

Selinexor: Dose-escalating oral regimens: Dose A: 40 mg once weekly (QW) . Dose B: 60 mg QW for 2 consecutive weeks, followed by 1 week off.

Trial Locations (1)

200032

RECRUITING

Dept of lymphoma and medical oncology, Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06966154 - A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL | Biotech Hunter | Biotech Hunter